TrialBlood neoplasia2025

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.

Martin Hutchings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.